Clinical Efficacy of Neuroendoscopic Endonasal Transsphenoidal Pituitary Adenoma Resection Combined with Octreotide in the Treatment of Patients with Pituitary Growth Hormone Adenoma
Objective To investigate the clinical efficacy of neuroendoscopic endonasal transsphenoidal pituitary adenoma resection combined with octreotide in the treatment of patients with pituitary growth hormone adenoma.Methods A total of 96 patients with pituitary growth hormone adenoma admitted to Huaian Hospital of Traditional Chinese Medicine from January 2021 to January 2023 were selected,and they were divided into the reference group(n=48)and the combined group(n=48)according to random number table method.Patients in the reference group were received neuroendoscopic endonasal transsphenoidal pituitary adenoma resection,and patients in the combined group were received octreotide for 1 year based on the reference group.Clinical efficacy,hypophyseal hormone levels[serum prolactin(PRL),adrenocorticotropic hormone(ACTH),growth hormone(GH),insulin-like growth factor 1(IGF-1)],main clinical symptoms scores,and scores of each dimension in 36-Item Short Form Health Survey(SF-36)before treatment and at 1 month after treatment were compared between the two groups,and incidence of complications and disease recurrence within 1 year of follow-up of the two groups were observed.Results At 1 year after treatment,the clinical efficacy in the combined group was better than that in the reference group(P<0.05).At 1 month after treatment,the serum levels of PRL,ACTH,GH and IGF-1,and scores of headache,blurred vision and sexual dysfunction in the combined group were significantly lower than those in the reference group(P<0.05).At 1 month after treatment,scores of overall health,physical role,body pain,physical function,social function,emotional role,mental health and vitality dimensions in the combined group were significantly higher than those in the reference group(P<0.05).There was no significant difference in the total incidence of complications between the two groups(P>0.05).The disease recurrence rate within 1 year of follow-up in the combined group was lower than that in the reference group(P<0.05).Conclusion Neuroendoscopic endonasal transsphenoidal pituitary adenoma resection combined with octreotide have exact clinical effect in the treatment of patients with pituitary growth hormone adenoma,which can effectively improve the patients'pituitary function,relieve the degree of clinical symptoms,improve quality of life,reduce disease recurrence rate,and with a certain safety.
万方数据
维普
